Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Olfson

Showing results (101-110 of 683) with videos related to

Pageof 69
Sort By:
JAMA|June 1, 2021
Risks and Benefits of Benzodiazepines-ReplyMatthew E Hirschtritt, Mark Olfson, Kurt Kroenke
American Journal of Public Health|March 29, 2022
Research Opportunities That Maximize Public Health Impact on the Opioid Overdose EpidemicCarlos Blanco, Melanie M Wall, Mark Olfson
Journal of the American Academy of Child and Adolescent Psychiatry|October 22, 2020
Trends in Antipsychotic Medication Use in Young Privately Insured ChildrenGreta A Bushnell, Stephen Crystal, Mark Olfson
The American Journal of Psychiatry|March 2, 2018
Medical Marijuana and the Opioid Epidemic: Response to Theriault and SchlesingerMark Olfson, Melanie M Wall, Carlos Blanco
Journal of General Internal Medicine|June 17, 2020
Psychological Aspects of the COVID-19 PandemicCarlos Blanco, Melanie M Wall, Mark Olfson
JAMA Psychiatry|May 21, 2020
Risks of Mortality Following Nonfatal Intentional and Unintentional Opioid OverdosesMark Olfson, Michael Schoenbaum, Sidra Goldman-Mellor
Psychiatric Services (Washington, D.C.)|May 5, 2009
Antidepressant switching among adherent patients treated for depressionSteven C Marcus, Mariam Hassan, Mark Olfson
Journal of the American Academy of Child and Adolescent Psychiatry|September 22, 2010
National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007Jonathan S Comer, Mark Olfson, Ramin Mojtabai
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|June 6, 2013
Prescribing of psychotropic medications to children and adolescents: quo vadis?Christoph U Correll, Tobias Gerhard, Mark Olfson
JAMA Psychiatry|February 5, 2015
Assessing and improving clinical insight among patients "in denial"Arthur Robin Williams, Mark Olfson, Marc Galanter
Pageof 69

Showing results (101-110 of 683) with videos related to

Sort By:
Pageof 69
JAMA|June 1, 2021
Risks and Benefits of Benzodiazepines-ReplyMatthew E Hirschtritt, Mark Olfson, Kurt Kroenke
American Journal of Public Health|March 29, 2022
Research Opportunities That Maximize Public Health Impact on the Opioid Overdose EpidemicCarlos Blanco, Melanie M Wall, Mark Olfson
Journal of the American Academy of Child and Adolescent Psychiatry|October 22, 2020
Trends in Antipsychotic Medication Use in Young Privately Insured ChildrenGreta A Bushnell, Stephen Crystal, Mark Olfson
The American Journal of Psychiatry|March 2, 2018
Medical Marijuana and the Opioid Epidemic: Response to Theriault and SchlesingerMark Olfson, Melanie M Wall, Carlos Blanco
Journal of General Internal Medicine|June 17, 2020
Psychological Aspects of the COVID-19 PandemicCarlos Blanco, Melanie M Wall, Mark Olfson
JAMA Psychiatry|May 21, 2020
Risks of Mortality Following Nonfatal Intentional and Unintentional Opioid OverdosesMark Olfson, Michael Schoenbaum, Sidra Goldman-Mellor
Psychiatric Services (Washington, D.C.)|May 5, 2009
Antidepressant switching among adherent patients treated for depressionSteven C Marcus, Mariam Hassan, Mark Olfson
Journal of the American Academy of Child and Adolescent Psychiatry|September 22, 2010
National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007Jonathan S Comer, Mark Olfson, Ramin Mojtabai
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|June 6, 2013
Prescribing of psychotropic medications to children and adolescents: quo vadis?Christoph U Correll, Tobias Gerhard, Mark Olfson
JAMA Psychiatry|February 5, 2015
Assessing and improving clinical insight among patients "in denial"Arthur Robin Williams, Mark Olfson, Marc Galanter
Pageof 69